Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score-Reference-Cited by-同舟云学术

Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score

Published:2019-06-14 Issue:9 Volume:8 Page:4169-4175
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Gaiser Maria R.¹²^ORCID,Lorenzen Sylvie³,Merx Kirsten⁴,Trojan Jörg⁵^ORCID,Ocvirk Janja⁶,Ettrich Thomas J.⁷,Al‐Batran Salah‐Eddin⁸,Schulz Holger⁹,Homann Nils¹⁰,Feustel Hans‐Peter¹¹,Schatz Michael¹²,Kripp Melanie⁴,Schulte Nadine⁴,Heeger Steffen¹³,Vlassak Soetkin¹⁴,Koch Winfried¹⁵,Hofheinz Ralf‐Dieter⁴

Affiliation:

1. Department of Dermatology, Venereology and Allergology University Medical Center Mannheim, Ruprecht‐Karl University of Heidelberg Mannheim Germany

2. Skin Cancer Unit German Cancer Research Center (DKFZ) Heidelberg Germany

3. Medical Clinic III University of Munich Munich Germany

4. Interdisciplinary Tumor Center Mannheim University Medical Center Mannheim, Ruprecht‐Karl University of Heidelberg Mannheim Germany

5. Medical Clinic I University Hospital Frankfurt Frankfurt Germany

6. Institute of Oncology Ljubljana Slovenia

7. Medical Clinic I University Hospital Ulm Ulm Germany

8. Institute of Clinical Cancer Research (IKF) at Nordwest Hospital UCT‐University Cancer Center Frankfurt Germany

9. Oncological Practice Frechen Germany

10. Medical Clinic II Wolfsburg Wolfsburg Germany

11. Hämatologisch‐Onkologische Praxis Speyer Germany

12. Medizinische Klinik II, ViDia Christliche Kliniken Karlsruhe Karlsruhe Germany

13. Mannheim Germany

14. Neervelp Belgium

15. BDS Koch Schwetzingen Germany

Funder

Merck KGaA

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2132

Reference13 articles.

1. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors

2. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

3. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors

4. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP

5. EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Menahydroquinone-4 may play a key role in regulating CCL5 expression induced by epidermal growth factor receptor inhibitors;Scientific Reports;2023-12-13

2. Effects of Sex and Seasonal Climatic Changes on the Risk of Incidence of Anti-EGFR Therapy-Induced Rash in Cancer Patients: A Retrospective Study;Medicina;2021-08-04

3. Overcoming the Photochemical Problem of Vitamin K in Topical Application;Vitamin K - Recent Advances, New Perspectives and Applications for Human Health [Working Title];2021-08-03

4. Ester derivatives of phyllohydroquinone effectively deliver the active form of vitamin K1 topically, owing to their non-photosensitivity;European Journal of Pharmaceutical Sciences;2020-12

5. Dermatological side effects of targeted antineoplastic therapies: a prospective study;Cutaneous and Ocular Toxicology;2020-10-01